Edwards Lifesciences (Irvine, California) has won an important battle in a six-year patent war with Medtronic (Minneapolis) over Medtronic's CoreValve transcatheter aortic valve replacement (TAVR/TAVI) system.
Boston Scientific (Natick, Massachusetts) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise deep brain stimulation (DBS) system in patients with Parkinson's disease.
The BioZorb three-dimensional surgical marker improved the ability of radiation oncologists to target radiation treatment for breast cancer, according to a presentation at this year's American Brachytherapy Society (ABS; Reston, Virginia) annual meeting earlier this month in San Diego.
Medtronic (Minneapolis) stole the show in London this past weekend with results from a landmark clinical study showing that its IN.PACT Admiral drug-coated balloon outperformed standard balloon angioplasty in patients with peripheral artery disease (PAD) in the upper leg.
St. Jude Medical (St. Paul, Minnesota) said the FDA has approved its Protégé IPG. According to the company, Protégé is the first neurostimulation system that allows spinal cord stimulation (SCS) technology upgrades as they are approved to be made via software updates. Chronic pain sufferers implanted with this new device can access innovative therapies, stimulation modes, diagnostics or other features once approved through future software upgrades without the need to surgically replace their medical device. Until now, one of the greatest challenges with neurostimulation has been giving patients access to the latest technologies without surgically replacing their device, St. Jude said.
